

research article

Impact factors for perioperative morbidity and mortality and repercussion of perioperative morbidity and long-term survival in pancreatic head resection

Stojan Potrc¹, Arpad Ivanecz¹, Vid Pivec, Urska Marolt¹, Sasa Rudolf², Bojan Iljevec¹, Tomaz Jagric¹

¹ Department of Abdominal Surgery, Surgical Clinic, University Medical Centre Maribor, Maribor, Slovenia

² Department of Radiology, University Medical Centre Maribor, Maribor, Slovenia

Radiol Oncol 2018; 52(1): 54-64.

Received 11 June 2017

Accepted 9 August 2017

Correspondence to: Assoc. Prof. Stojan Potrc, M.D., Ph.D., Department of Abdominal Surgery, Surgical Clinic, University Medical Centre Maribor, Ljubljanska 5, 2000 Maribor, Slovenia. Phone: +386 2 321 1301; Fax: +386 2 321 1257; E mail: potrc13@gmail.com

Disclosure: No potential conflicts of interest were disclosed.

Background. The focus of the present study was to reveal any impact factors for perioperative morbidity and mortality as well as repercussion of perioperative morbidity on long-term survival in pancreatic head resection.

Patients and methods. In a retrospective study, clinic-pathological factors of 240 patients after pancreatic head (PD) or total resection were analyzed for correlations with morbidity, 30- and 90-day mortality, and long-term survival. According to Clavien-Dindo classification, all complications with grade II and more were defined as overall complications (OAC). OAC, all surgical (ASC), general (AGC) and some specific types of complications like leaks from the pancreatoenteric anastomosis (PEA) or pancreatic fistula (PF, type A, B and C), leaks from other anastomoses (OL), bleeding (BC) and abscesses (AA) were studied for correlation with clinic-pathological factors.

Results. In the 9-year period, altogether 240 patients had pancreatic resection. The incidence of OAC was 37.1%, ASC 29.2% and AGC 15.8%. ASC presented themselves as PL, OL, BC and AA in 19% (of 208 PD), 5.8%, 5.8%, and 2.5% respectively. Age, ASA score, amylase on drains, and pancreatic fistulas B and C correlated significantly with different types of complications. Overall 30- and 90-day mortalities were 5 and 7.9% and decreased to 3.5 and 5% in P2.

Conclusions. High amylase on drains and higher mean age were independent indicators of morbidity, whereas PL and BC revealed as independent predictor for 30-day mortality, and physical status, OAC and PF C for 90-day mortality.

Key words: pancreatic resections; complications; impact factors

Introduction

Resection of the head of pancreas remains a significant challenge for many pancreaticobiliary surgeon. Recently, better perioperative care, surgical technique, and better patient's selection have undoubtedly led to better survival and have reduced the perioperative mortality. However, the high morbidity that accompanies these operations negates any positive long-term results in patients with otherwise poor prognosis that could have benefited from.

The complications associated with PD procedures are well described.^{1,2} These are usually of higher grade than in comparable abdominal surgical procedures. Even more, they are usually associated with significant perioperative morbidity. Many attempts have been made to lower these complications.^{1,3-7} Some authors have claimed that modifications of the surgical techniques, especially the formation of the pancreatojejunostomy, could have a positive impact on the postoperative course. Others have claimed that a better selection of patients would decrease the morbidity and mortal-

ity.⁸⁻¹³ Since perioperative morbidity and mortality are important predictors for long-term survival of patients after PD's^{14,15}, we performed a retrospective study to determine factors associated with perioperative and specific surgical complications, general complications, and perioperative mortality. The identification of such negative prognostic factors could help to prevent complications or even mortality and could therefore have an impact on long-term survival after pancreatic surgery.

Factors like postoperative pancreatic fistula, age, and poor general condition have all been determined to have a negative impact on the postoperative course.^{1,4,13,16,17} The drawbacks of some of these studies, however, are the small number of included patients, the inclusion of low-volume centers, and the short-term postoperative follow-up of the patients. In our study, we therefore evaluated which clinic-pathological factors significantly influence morbidity, mortality, and long-term results in a tertiary reference institution for pancreatic diseases, where about 50 pancreatic resections are performed annually. Preoperative workup, surgical procedures, and postoperative care are highly standardized. All these factors enabled us to perform a detailed study of factors influencing the perioperative course after pancreatic surgery.

Patients and methods

For the present retrospective study, the data of patients after pancreaticoduodenectomies (PD) and total pancreatectomies (TP) performed from January 1, 2008 to March 31, 2017 at the Department of Abdominal Surgery UMC Maribor were analyzed. Clinical and pathological data were prospectively stored in a computerized database. Data for the follow-up were obtained by our own outpatient follow-up and by the National cancer register of Slovenia. Complete follow-up was obtained up to June 1, 2017. We obtained informed consent from all patients and performed all procedures according to the guidelines of the Helsinki Declaration. The analysis includes patients having had PD and TP. There are no urgent resections included. The indications for the resection were malignant and premalignant lesions of the region sited in the head of pancreas, and chronic pancreatitis in few cases.

Preoperative workup

Patients' preoperative physical status was expressed by the American Society of Anesthesiology

score (ASA).¹⁸ Three ASA 4 patients from this period were not included in the study. Prior to the surgery, all patients were submitted to computer tomography (CT). Additional abdominal magnetic resonance imaging (MR) or endo-ultrasonography (EUS) with or without biopsy were done only in selected patients. Beside usual standard laboratory blood tests, tumor markers CEA and Ca 19-9 were also evaluated. Preoperative endoscopic biliary drainage (EBD) was done in patients with bilirubin value > 200 mmol/l or in subicteric patients when further preoperative workup was necessary.

Preoperative preparation

Intravenous antibiotic (1.5 g cefuroxime and 0.5 g metronidazole or 0.35 g gentamycin and 0.6 g clindamycin) and subcutaneous antithrombotic (4000 IE enoxaparin or 3800 nadroparin or 5000 IE dalteparine) prophylaxis were successively used in all patients 1 hour and 12 hours prior to operation. Urine catheter and nasogastric tube were usually inserted after induction of anesthesia.

Surgical technique

The usual operative approach was median or bilateral subcostal laparotomy. After confirming resectability (no distant dissemination, no tumor infiltration of the coeliac trunk, hepatic artery or superior mesenteric artery), the strategy was to perform a curable resection (R0) in malignant and premalignant lesions, and/or to relieve symptoms as in chronic pancreatitis. Usually pylorus-preserving PD, Whipple resection or TP (in patients with very soft texture of the pancreas unsuitable for anastomosis) were performed. In malignant disease, lymphadenectomy was done in hepatoduodenal ligament, around common hepatic artery, superior mesenteric artery (usually 180 to 270°), and occasionally between vena cava and aorta. Resection borders on the bile duct and pancreas were checked for neoplastic infiltration by frozen section examination. If infiltration of the superior mesenteric or portal vein was suspected, "En-block" resection of the infiltrated vein was done to assure the curability of resection. Vascular reconstruction was done by direct continuous 6.0 monofilament non-absorbable suture; however, if more extended distance had to be bridged, vascular prosthesis was used. Anastomosis to pancreatic stump was exclusively performed by duct to mucosa end to side pancreaticoenteric anastomosis (PEA) using 5.0 monofilament non-absorbable

TABLE 1. Indications for pancreatic resection

| Indication for pancreatic resection | P1 (n/ %) | P2 (n/ %) | All (n/ %) | P |
|---|--------------|--------------|---------------|---|
| Pancreatic adeno carcinoma | 64 66.7% | 71 50.0% | 135 56.7% | |
| Neuroendocrine tumor of the pancreas | 2 2.1% | 7 4.9% | 9 3.8% | |
| Main duct intraductal papillary mucinous neoplasm | 0 0.0% | 3 1.4% | 3 0.8% | |
| Franz's tumor | 1 1.0% | 0 0.0% | 1 0.4% | |
| Non-Hodgkin lymphoma of the pancreas | 1 1.0% | 1 0.7% | 2 0.8% | |
| Adenocarcinoma of the distal bile duct | 13 13.5% | 30 20.8% | 43 17.9% | |
| Adenocarcinoma of the papilla Vateri | 12 12.5% | 18 12.5% | 30 12.5% | |
| Duodenal adenocarcinoma | 2 2.1% | 6 4.2% | 8 3.3% | |
| Gastric cancer | 0 0.0% | 2 1.4% | 2 0.8% | |
| Chronic pancreatitis | 1 1.0% | 6 4.2% | 7 2.9% | |

P1 (period 1) = from January 1, 2008 to December 31, 2012 (96 pts); P2 (period 2): from January 1, 2013 to March 31, 2017

sutures in two layers followed by single-layer bilioenteric anastomosis (BEA) with interrupted 5.0 absorbable polyfilament sutures. In selected patients (mostly with thin duct and/or soft texture of the pancreas), trans-anastomotic lost stent was used. The continuity of the gastrointestinal tract was further established by omega gastroenteric anastomosis (GEA) done with 3.0 absorbable monofilament sutures. In all patients, single-layer continuous enterocenteric anastomosis (EEA) between afferent and efferent loop was done with 4.0 polyfilament absorbable suture. Two drains were placed in the right subhepatic region (one in space of resected head of the pancreas and one above bilioenteric anastomosis) and one in the Douglas region.

Postoperative care

Almost all patients were admitted in the high dependency unit except if admission to the intensive care unit was indicated. Patients started to receive fluid food on the first day. Gastric tube

was removed after appearance of bowel movements or the first stools. Amylase was checked in the drained fluid on day 3 and thereafter when any clinical suspicion for anastomotic leaks was present. In selected patients (soft pancreas remnant) however, parenteral somatostatin (6 mg/24 h) was administrated for 6 to 10 days in the presence of clinical relevant amylase leak until the cessation of secretion on abdominal drains.

Definitions and statistical analyses

All complications (OAC) according to Clavien-Dindo classification grade II or more were considered as postoperative morbidity.¹⁹

All surgical (ASC), all general (AGC), and all surgical and general complications (SGC) were analyzed. In addition, special group of complications like leak from PEA (PL), leaks not from PEA (OL), abdominal abscess (AA) and abdominal or intestinal bleeding (BC) were identified.

Any postoperative mortality within 30 and 90 days was considered a probable consequence of

TABLE 2. Observed clinicopathological features in 240 operated patients

| | | P1 (n/%) | P2 (n/%) | All (n/%) | P |
|---|---------------------------|-------------|--------------|--------------|--------|
| Gender (n = 240) | male | 51 53.1% | 80 55.6% | 131 54.6% | 0.4 |
| | female | 45 46.9% | 64 44.4% | 109 45.4% | |
| Age (n = 240) | Mean (years) | 66.1 ± 9.9 | 65.98 ± 10.1 | 66.4 | 0.91 |
| ASA (n = 240) | 1 | 17 17.7% | 43 29.9% | 17 17.7% | 0.103 |
| | 2 | 53 55.2% | 68 47.2% | 53 55.2% | |
| | 3 | 26 27.1% | 33 22.9% | 26 27.1% | |
| Preoperative histology (n = 240) | | 4 4.2% | 32 22.2% | 36 15.0% | 0.0001 |
| Hospital stay (n = 222) | Mean (days) | 21.2 ± 14.5 | 19 ± 11.6 | 19.8 | 0.138 |
| Preoperative total bilirubin (n = 240) | Mean (mmol/l) (mmol/l) | 67.6 ± 71.5 | 79.0 ± 85.5 | 74.7 | 0.028 |
| Preoperative endoscopic biliary drainage (EBD) (n = 240) | | 34 35.4% | 51 35.4% | 85 35.4% | 0.554 |
| | | P1 (n/%) | P2 (n/%) | All (n/%) | p |
| Type of pancreatic resection (n = 240) | PD | 92 95.8% | 115 79.9% | 207 86.3% | 0.0001 |
| | TP | 4 4.2% | 29 20.8% | 33 14.2% | |
| Resection of VMS/VP (n=240) | | 12 12.5% | 28 19.4% | 40 16.7% | 0.17 |
| Type of vascular reconstruction (n=240) | Direct suture | 10 10.4% | 14 9.7% | 24 10.0% | 0.043 |
| | Vascular graft | 2 2.1% | 14 9.7% | 16 6.7% | |
| Overall complications (OAC) (n=240) | | 34 35.4% | 55 38.2% | 89 37.1% | 0.383 |
| 30-day mortality (n=240) | | 7 7.3% | 5 3.5% | 12 5.0% | 0.152 |
| 90-day mortality (n=240) | | 11 11.5% | 8 5.6% | 19 7.9% | 0.080 |

ASA = American Society of Anesthesiologist Physical Status; VMS = mesenteric superior vein; VP = portal vein; P1 (period 1) = from January 1, 2008 to December 31, 2012 (96 pts); P2 (period 2): from January 1, 2013 to March 31, 2017

surgery and was declared as postoperative mortality (30- and 90-day mortality).

Receiver operating curve analysis for morbidity and mortality determined the threshold values of amylase secretion on abdominal drains. An area under curve (AUC) of > 0.75 was used to determine

the value of significance. The ROC analysis was used to determine sensitivity and specificity of the determined amylase cut-off, which revealed to be more than 7 ukat/l. Sensitivity and specificity for prediction of pancreatic fistula type B or C (PF B or C) at cut-off 7 ng/ml were 100% and 85.4% re-

TABLE 3. Surgical complications in 240 operated patients

| Type of all surgical complications (n = 240) | n | % | % 90-day mortality |
|--|------------|--------------|--------------------|
| No surgical complications | 169 | 70.4 | 3 |
| PF B or C | 28 | 11.7 | 25 |
| PF B or C and bleeding | 8 | 3.3 | 62.5 |
| Bleeding in the intestines | 2 | 0.8 | 0 |
| Intraabdominal bleeding – no PF | 4 | 1.7 | 25 |
| Bile leak | 10 | 4.2 | 0 |
| Leak from GEA | 5 | 2.1 | 20 |
| Dehiscence of laparotomy | 3 | 1.3 | 0 |
| Intraabdominal abscess | 6 | 2.5 | 0 |
| Ileus | 1 | 0.4 | 0 |
| Thrombosis of vascular graft | 2 | 0.8 | 0 |
| Volvulus coeci | 1 | 0.4 | 0 |
| Stenosis of coeliac trunk | 1 | 0.4 | 0 |
| Total | 240 | 100.0 | 7.9% |

GEA = gastroenteroanastomosis; PF B and C = pancreatic fistula type B and C

TABLE 4. General complications in 240 operated patients

| Type of all general complications (n = 240) | n | % | % 90-day mortality |
|---|------------|--------------|--------------------|
| No general complications | 202 | 84.2 | 5.0 |
| Pneumonia | 8 | 3.3 | 25 |
| Cardiorespiratory decompensation | 3 | 1.3 | 100 |
| Heart failure | 9 | 3.8 | 11.1 |
| Pulmonary embolism | 4 | 1.7 | 25 |
| Different infections | 10 | 4.2 | 10 |
| Renal failure | 1 | .4 | 100 |
| Brain stroke | 1 | .4 | 0 |
| Miscellaneous | 2 | .8 | 0 |
| Total | 240 | 100.0 | 7.9 |

spectively. Consequently, any secretion of amylase rich fluid on drains more than 7 ukat/l was defined as elevated. Patients with high amylase on drains from PEA were declared to have (PF) and retrograde classified in three types of PF (A, B, C) respecting clinical picture, therapeutic consequences, and ISGPF PF recommendations.²⁰

Two chronologically successive groups of patients (period 1 (P1): from January 1, 2008 to December 31, 2012 (96 pts); and period 2 (P2): from January 1, 2013 to March 31, 2017 (144 pts)) were compared for perioperative morbidity, and 30- and 90-day mortality.

Continuous data are expressed as mean \pm standard deviation and categorical variables are given as

percentages. Continuous variables were compared with Student's t-tests for parametric data and Mann-Whitney U tests for nonparametric data. Chi-square tests were used for comparisons of discrete variables.

All of the predictors that were significant on univariate analysis were included in the multivariate analysis. In the multivariate analysis, a binary logistic model was used. Survival analysis was performed with the Kaplan-Meier method. The differences between groups were compared with the log-rank test. P values < 0.05 were defined as the limit of significance. For statistical analysis, SPSS version 22 for Windows 7 (IBM Analytics, Armonk, NY) was used.

The aim of our study was to evaluate the incidence of morbidity and mortality, and to reveal any correlations with clinicopathological factors. In addition to morbidity and mortality, the impact of morbidity and mortality on survival was studied. The second aim was to reveal any differences between two chronologically successive groups (P1 and P2).

Results

Altogether 240 patients had pancreatic resection (male 131, female 109, mean age 66.04 years). The indications for resections and characteristics of the analyzed patients are presented in Tables 1 and 2.

The incidence of OAC was 37.1%. ASC occurred in 29.2% whereas AGC in 14.2%. ASC presented themselves as a leak from PEA (PL), non-PEA leak (OL), bleeding complications (BC) and abdominal abscesses (AA) in 19% (of 208 PD), 5.8%, 5.8% and 2.5% respectively. In case of OL, five were from GEA. Bleeding (BC) occurred in altogether 14 of 240 patients. Two patients had early intestinal bleeding and 12 occurred after 24 hours. Other rare surgical complications occurred in altogether 4.5% (Table 3). All general complications are described in Table 4.

Drained fluid was checked for amylase in 189 of 207 patients after PD. Elevated amylase more than 7 ukat/l on drains were found in 73 patients (38.6%). In 63 patients (33.3%), the high amylase on drains originated from PEA whereas in 10 patients amylase rich secretion evidently did not originate from PEA (6 bile leaks, 2 leaks from GEA, 1 ileus, 1 strangulation of the mobile cecum). The rate of PF A was 14.4%, PF B 9.6% and PF C 9.6%. Determination of PF in groups A, B and C did not correlate with means of amylase value in dis-

TABLE 5. Correlation of clinicopathological factors and perioperative morbidity and mortality in 240 operated patients

| | N | | OAC | P | ASC | P | BC | P | OL | P | AA | P | PL | P | AGC | P |
|--------------------------|-----|---------------------------|--|---------------|--|---------------|-------------------------------------|---------------|-------------------------------------|---------------|-------------------------------------|---------------|--------------------------------------|---------------|--------------------------------------|---------------|
| Age (years) | 240 | No compl. Compl. | 64.6 ± 10 68.4 ± 9.1 | 0.005 | 65.3 ± 10.3 67.9 ± 9.1 | 0.051 | 66.2 ± 10 63.5 ± 12 | 0.452 | 66 ± 10 67.1 ± 8 | 0.665 | 65 73 | 0.056 | 65.7 ± 10 67.3 ± 8 | 0.256 | 65.4 ± 10 70.1 ± 9 | 0.007 |
| Age (<70 and >69) | 240 | <70 >69 | 28.6% 43.7% | 0.011 | 23.8% 33.3% | 0.071 | 8.6% 3.7% | 0.094 | 4.8% 6.7% | 0.369 | 0% 100% | 0.030 | 16.3% 21.4% | 0.234 | 8.6% 18.5% | 0.021 |
| ASA 1.2 vs. 3 | 240 | ASA 1+2 ASA 3 | 32% 52.5% | 0.004 | 23.8% 33.3% | 0.042 | 5.5% 6.8% | 0.465 | 5.5% 6.8% | 0.465 | | 0.457 | 16.1% 29.5% | 0.042 | 10.5% 25.4% | 0.006 |
| Total bilirubin (mmol/l) | 240 | No compl. Compl. | 70.1 ± 74 82.9 ± 89 | 0.271 | 68.3 ± 73.6 89.5 ± 93.1 | 0.062 | 71 ± 77 134 ± 104 | 0.005 | 74.4 ± 78 75.5 ± 108 | 0.969 | | 0.231 | 68.1 ± 70 91.4 ± 99 | 0.195 | 79 ± 82 47.4 ± 61 | 0.033 |
| EBD (no/yes) | 240 | No EBD EBD | 33.5% 43.5% | 0.082 | 24.5% 37.6% | 0.024 | 5.8% 5.9% | 0.594 | 7.1% 3.5% | 0.203 | | 0.640 | 12.8% 30% | 0.004 | 11.6% 18.8% | 0.092 |
| PD/TP | 240 | PD TP | 37.2% 36.4% | 0.545 | 29.5% 27.3% | 0.488 | 6.3% 3% | 0.400 | 5.8% 6.1% | 0.600 | 1% 12.1% | 0.004 | - - | - - | 13% 21.2% | 0.126 |
| Vasc. resect. (yes/no) | 240 | No vasc. Vasc. resect. | 39.5% 27.5% | 0.115 | 30.0% 25.0% | 0.334 | 4.5% 12.5% | 0.063 | 6% 5% | 0.578 | | 0.738 | 21.1% 7.7% | 0.083 | 16.5% 2.5% | 0.011 |
| Size of tumor (mm) | 201 | No compl. Compl. | 32.3 ± 19 24.6 ± 12 | 0.001 | 31.7 ± 18.8 23.7 ± 10.1 | 0.002 | 29.5 ± 17 25 ± 10 | 0.187 | 29.4 ± 17 25.1 ± 13 | 0.320 | | 0.069 | 30.3 ± 18 22.5 ± 9 | 0.001 | 29.7 ± 17 25.7 ± 15 | 0.211 |
| Type of tumor PAC/NPC | 216 | PAC NPC | 34.1% 46.9% | 0.042 | 26.7% 37.0% | 0.074 | 6.7% 4.9% | 0.421 | 5.9% 7.4% | 0.435 | | 0.403 | 16.2% 25.7% | 0.092 | 69.8 ± 183 83.5 ± 127 | 0.094 |
| Amylase level (ukat/l) | 187 | No compl. Compl. | 21.3 ± 62.1 150.6 ± 252 | 0.0001 | 24.0 ± 73 179.9 ± 270 | 0.0001 | 68.6 ± 175 128.1 ± 199 | 0.333 | 72.3 ± 180 62.5 ± 100 | -0.773 | 72.5 ± 177 1.1 ± 1 | 0.0001 | 22.2 ± 70 260 ± 310 | 0.0001 | 69.8 ± 183 83.5 ± 127 | 0.640 |
| Amylase (>7 ukat/l) | 187 | < 7 > 7 | 20.2% 69.8% | 0.0001 | 11.4% 61.6% | 0.0001 | 3.5% 12.7% | 0.022 | 1.7% 60.3% | 0.0001 | | 0.529 | 19.1% 100% | 0.0001 | 35.6% 57.7% | 0.033 |
| PF C (yes/no) | 187 | No PF C PF C | 33.1% 100% | 0.0001 | 23.7% 100% | 0.0001 | 3% 38.9% | 0.0001 | | 0.318 | | 0.818 | 10.7% 100% | 0.0001 | - | 0.464 |
| PF B (yes/no) | 187 | No PF B PF B | 33.1% 100% | 0.0001 | 23.7% 100% | 0.0001 | 6.5% 5.6% | 0.676 | | 0.318 | | 0.818 | 10.7% 100% | 0.0001 | - | 0.221 |
| PF A (yes/no) | 187 | No PF A PF A | 42.5% 22.2% | 0.035 | 36.3% 0 | 0.0001 | | 0.148 | | 0.171 | | 0.734 | 24% 100% | 0.0001 | - | 0.141 |
| PF B or C | 187 | No PF B+C PF B+C | 25.2% 100% | 0.0001 | 14.6% 100% | 0.0001 | 2.6% 22.2 | 0.0001 | | 0.088 | | 0.655 | | | | |
| Period of the study | 240 | P1 P2 | 35.4% 38.2% | 0.383 | 25.0% 31.9% | 0.155 | 2.1% 8.3% | 0.036 | 5.2% 6.3% | 0.485 | | 0.230 | 16.9% 21.2% | 0.292 | 17.7 11.8 | 0.137 |
| Hospital stay (days) | 240 | | 14.2 ± 4 31.4 ± 16 | 0.0001 | 15.2 ± 6 32.9 ± 17 | 0.0001 | 19.3 ± 13 31.9 ± 8 | 0.003 | 18.1 ± 9 44.9 ± 29 | 0.0001 | 19.6 ± 13 29 ± 10 | 0.075 | 17.8 ± 12 30.7 ± 9 | 0.0001 | 18.4 ± 12 30.9 ± 10 | 0.0001 |

AA = intraabdominal abscess; ASC = all surgical complications; AGC = all general complications; BC = bleeding complications; comp. = complications; EBD = external biliary drainage; No compl. = no complications; NPC = non-pancreatic carcinoma; OAC = overall complications; OL = other anastomotic leak; PAC = pancreatic adenocarcinoma; PD = pancreaticoduodenectomy; PL = pancreatic leak anastomosis; PF C/ B/ A = pancreatic fistula type C/ B/ A; TP = total pancreatectomy; Vasc. resect. = vascular resection; No vasc. = no vascular resection

charged secretion on drains in ordinal fashion; it was rather the consequence of clinical factors and therapeutic measures.

One of the common consequences of complications was significantly prolonged hospital stay (OAC: 30.9 ± 16 vs. 14.2 ± 4.5 days; $p < 0.0001$). Overall 30- and 90-day mortality were 5% and 7.9%.

Correlation of clinicopathological factors and perioperative morbidity

Age and physical status

Patients with OAC and AGC were older, and their physical status according to ASA was worse. Physical status was worse also in a group of patients with PL (29.5% vs. 16.1%; $p = 0.042$). Regarding this, no correlations were found in other subsets of complications (AA, BC, and OL) (Table 5).

Preoperative bilirubin value and EBD. At our disposal were only bilirubin values from the period within a week before the PD, and the majority of patients was transferred to our institution with already placed EBD more than 1 week before the operation. This prevented us to make any conclusive analysis on this issue. Generally, patients with preoperative placed EBD had lower mean preoperative bilirubin values than those without EBD (57.4 ± 66 vs. 83.8 ± 86 mmol/l; $p = 0.005$). Increased mean bilirubin level was noted in BC (134.7 ± 104 vs. 70.7 ± 71.6 mmol/l; $p = 0.005$). EBD was in 37.6% of our patients associated with the occurrence of ASC and in 30% with PL (ASC: 37.6% vs. 24.5%, $p = 0.024$, PL: 30% vs. 12.5%, $p = 0.004$), but there have been no correlations of EBD with other settings of complications (Table 5).

Type of resection and vascular resections

PD and TP were comparable regarding all clinicopathological factors except of AA which was more likely after TP (1% vs. 12.1%; $p = 0.004$). Resections of VMS/VP correlated only with AGC revealing even less complications if vascular resection has been done (2.5% vs. 16.5%; $p = 0.011$). This correlation was difficult to explain since patients with vascular resection were comparable regarding the age and physical status (mean age: 65.2 vs. 66.1 years; $p = 0.556$; ASA 3 vs. ASA 1 and 2: 22.2% vs. 25%; $p = 0.456$) (Table 5).

Type and size of the tumor

Data of tumor dimensions were available for 201 patients. There was a high correlation between tumor size and tumor type revealing NPCs to be smaller and PACs to be larger. In groups of OAC, ASC and PL, smaller size of tumor significantly predicted the onset of complications. Calculation revealed that patients with NPC were more prone for onset of OAC than those with PAC (Table 5).

Amylase on drains

Complications after PD were associated with amylase rates more than 7 ukat/l. The mean amylase value was increased only in OAC and ASC (OAC: 150.6 ± 252 vs. 21 ± 62 ; $p < 0.0001$, ASC: 179.9 ± 270 vs. 24 ± 73 ; $p < 0.0001$). Since PF A has never been noticed, it did not have any negative impact on any type of complications. There is an inverse correlation of mean amylase level and AA ($1.1 \pm 72.5 \pm 177$ ukat/l; $p < 0.0001$) proving that abscesses did not originate from pancreatic leak. Smaller size of the tumor proved to be a predictor for the occurrence of PL (30.3 ± 18 vs. 22.5 ± 9 ; $p = 0.001$). Amylase rates more than 7 ukat/l and PF B were more often noted in NPCs (amylase < 7 ukat/l: 48.4% vs. 25.3%; $p = 0.002$, PF B: 17.2% vs. 6.3%; $p = 0.029$), but there was no correlation at the whole between PF C and type of tumor (Table 5).

Correlation of clinicopathological factors and perioperative mortality

Patients who suffered complications in terms of OAC, ASC, AGC, BC, PL and PF C were at a significant higher risk for postoperative mortality (OAC 30-day: 13.5% vs. 0%; $p < 0.0001$, OAC 90-day: 20% vs. 0.7%; $p < 0.0001$, ASC 30-day: 14.3% vs. 1.2%; $p < 0.0001$, ASC 90-day: 20% vs. 2.9%; $p < 0.0001$, AGC 30-day: 14.1% vs. 4.3%; $p < 0.0001$, AGC 90-day: 20% vs. 2.9%; $p < 0.0001$, BC 30-day: 35.7%

Vs. 3.1%; $p < 0.0001$, BC 90-day: 34.3% vs. 7.2%; $p < 0.0001$, PL 30-day: 22.2% vs. 2%; $p < 0.0001$, PL 90-day: 33.3% vs. 3.2%; $p < 0.0001$, PF C 30-day: 33.3% vs. 2.9%; $p < 0.0001$, PF C 90-day: 50% vs. 4.7%; $p < 0.0001$). On the other hand, OL and AA did not impact the 30- and 90-day mortality.

Age did not correlate to 30- or 90-day mortality; however, ASA physical status did (30-day: 11.9% vs. 2.8%; $p = 0.011$, 90-day: 18.6% vs. 4.4%; $p = 0.001$).

Patients with amylase rich secretion more than 7 ukat/l were also at a higher risk to die within 30 or 90 days after operation (amylase > 7 ukat/l 30-day: 14.3% vs. 1.7%; $p = 0.002$, amylase > 7 ukat/l 90-day: 20.6% vs. 3.4%; $p < 0.0001$). However, mean value of amylase on drains was significantly higher in patients that died within 90 days compared to those who died in 30 days (90-day: 172 ± 231 vs. 59.1 ± 170 ukat/l; $p = 0.013$). Tumor type or size of the tumor, mean preoperative total bilirubin, EBD, and PF A and B did not correlate with 30- and 90-day mortality.

Multivariate analysis

Predictors found to be significant for 30- and 90-day morbidity and mortality in the univariate analysis were included in the multivariate logistic regression analysis.

For OAC, higher mean age and drained amylase more than 7 ukat/l (age: CI 95%: 1.019-1.103; $p = 0.004$, amylase > 7 ukat/l: 95% CI: 0.045-0.204; $p < 0.0001$) were predictive. For ASC, higher mean amylases and drained amylase more than 7 ukat/l (mean amylase: 95% CI: 1.000-1.007; $p = 0.047$, 95%, amylase > 7 ukat/l: CI: 0.070 - 0.427; $p < 0.0001$) were specific. Moreover, for AGC, physical status, mean age and mean level of total bilirubin preoperatively (ASA: 95% CI: 1.007 -1.121; $p = 0.028$, mean age: 95% CI: 1.042-6.715; $p < 0.041$, mean total bilirubin: 95% CI: 0.981-0.999; $p < 0.027$) revealed as independent predictors.

For 30-day mortality, PL and BC revealed as independent predictors (PL: 95% CI: 0.026-0.522; $p = 0.005$, BC: 95% CI: 0.024-0.537; $p = 0.006$). In case of 90-day mortality, physical status, OAC and PF C (ASA: 95% CI: 1.404 -16.514; $p = 0.012$, OAC: 95% CI: 1.622-117.599; $p = 0.016$, PF C: 2.030-28.244, $p = 0.003$) were noticed as predictive factors.

Survival analyses

Patients who had OAC, ASC, AA, OL or AGC have had comparable expectation for long-term survival to those without complications (OAC: 866 ± 139

vs. 760 ± 174 days, Log Rank: $p = 0.242$; ASC: 866 ± 134 vs. 901 ± 216 days, Log Rank: $p = 0.234$; AA: Log rank: $p = 0.048$, OL: 836 ± 123 vs. 1159 ± 673 days; Log rank: $p = 0.760$, AGC: 866 ± 135 vs. 760 ± 197 days, Log Rank: $p = 0.431$). Complications like PL in PD and BC in all resected patients seriously compromised the expected long-term survival (PL: 938 ± 67 vs. 499 ± 146 days; Log Rank: $p = 0.010$, BC: 901 ± 128 vs. 409 ± 457 days; Log Rank: $p = 0.046$). On the other hand, in patients who survived complications, the long-term survival was not impacted by any type of complications (Figures 1,2).

Differences between two chronologically successive groups

Two chronologically successive groups of patients were comparable on most clinicopathological factors except for preoperative gained histology, preoperative total bilirubin, and type of resection (Table 2). The indications for TP were: postoperative bleeding from the pseudo-aneurism of the proximal part of the common hepatic artery combined with leak of the PEA (1 patient); PAC and main duct IPMN (9 patients); diffuse main duct IPMN (1 patient); very soft pancreas (10 patients); positive resection margins (5 patients); tumor extending to the body of the pancreas (5 patients); and formerly removed left pancreas (2 patients) (Table 1). Five out of 10 patients with extremely soft pancreas had also vascular reconstructions with prosthetic interposition, and three already had insulin dependent diabetes. The overall (P1 and P2) 30- and 90-day mortality in our cohort were 5 and 7.9% respectively. In P2, the rates for 30- and 90-day mortality became lower, 3.5% and 5% respectively, but the statistical difference between P1 and P2 reveals only borderline statistical value ($p = 0.08$) (Table 2).

Discussion

Pancreatic resections present the only curative option for patients with malignant and premalignant diseases, and for relief of symptoms in selected group of patients with chronic pancreatitis. However, due to high morbidity and mortality, the treatment should not be worse than the disease.²¹ Despite markedly progress on the field of pancreatic resections, morbidity remains quite high for decades whereas mortality rates gradually improved.²²⁻²⁷ There was no exception in our study with OAC rate of 37.1%; ASC 29.2% and

AGC 14.2% were AGC within the two observed periods. The 30- and 90-day mortality in our patients were 5% and 7.9% respectively. This result is well comparable to the reports of other authors. In many studies, postoperative mortality was defined traditionally as mortality within 30-days or during the initial hospitalization. This might had led to an underestimated postoperative morbidity and mortality rates. As shown by some Meta analyses, even in centers of Excellency, the 90-day mortality rate is double of the 30-day mortality rate and significantly differs concerning the hospital volume. One of the consequences of postoperative morbidity for patients who survive the complication was significantly prolonged hospitalization.^{5,15,26,28} In our study, it was ranging between 30 and 44 days.

It has been often documented that higher age and low physical status can significantly affect the occurrence of postoperative complications.^{12,13} In our study, higher mean age and higher ASA score impacted the incidence of OAC and AGC. ASA score alone impacted ASC and PL. Regarding our results, higher mean age was an independent predictor for OAC and AGC whereas ASA score was for AGC. On the other hand, specific complications like BC, AA and OL did not correlate with age or physical status. Age did not prove as an independent prognostic factor for any type of complications; however, ASA score did for 90-day mortality. Therefore, our results support the conclusion not to restrain patients from PD or TP only because of their age; however, caution is needed while selecting the patients for PD or TP.

There is an ongoing debate on whether jaundiced patients with obstructive lesion and higher bilirubin in the head of the pancreas should be drained or not.²⁹⁻³⁴ Since only relevant laboratory data from the immediate preoperative period were at our disposal for the study, we can hardly profoundly discuss this issue. Based on our own data, however, we observed higher mean total bilirubin values in patients with BC and lower for the group with AGC. The results regarding EBD match with the results from others revealing higher incidence of ASC and PL in patients with EBD.^{31,35-38} There was no correlation of mean total bilirubin or EBD with 30- and 90-day mortality.^{32,39,40}

Our study confirms comparable results regarding the perioperative morbidity and mortality between PDs and TPs except for abdominal abscesses, which occurred more often in TP. This fact could speak for TP in selected cases of patients with pancreas remnant untenable for PEA, especially in elderly in less good general condition who do not

tolerate this kind of complications at all.⁴¹⁻⁴³ In patients with preexisting insulin dependent diabetes, this decision could even be easier. Relevant criteria for decision-making in this regard are still missing. Further analyses are needed for long-term quality of life, especially concerning insulin dependent diabetes.⁴⁴⁻⁴⁶

Resection of VMS or VP for infiltration was formerly regarded as a relative contraindication for the PD. However, nowadays it presents a standard treatment and was performed in 16.7% of our patients. In our study, neither type of pancreatic resection nor the incidence of VMS/VP resection influenced the occurrence of postoperative morbidity and mortality.⁴⁷⁻⁵²

The proportion of chronic pancreatitis in PACs and NPCs included in the reports can differ significantly, and if cases with predominantly hard pancreas remnant predominate, as in patients with chronic pancreatitis, the overall risk for postoperative morbidity and mortality rates could reveal at a lower rates. In our collective of patients, chronic pancreatitis and PAC contributed 2.9 and 56.7% of patients respectively, remaining more than 40% of patients with diseases where the pancreas remnant could be softer (Table 1).^{9,53-55}

To our results, concerning only PACs and NPCs, OACs were more likely to occur in NPCs and in tumors of smaller size. Moreover, the majority of NPCs were also smaller than PACs. The size of tumor affects the onset of OAC, ASC and PL; however, neither 30- nor 90-day mortality were impacted by type or size of the tumor.⁵⁶⁻⁵⁸

Patients with amylase more than 7 ukat/l on drains and pancreatic fistula were retrospectively classified in three types of PF (A, B, C) respecting clinical picture, therapeutic consequences, and ISGPF PF recommendations.²⁰ Mean values of amylase in discharged secretion did not differ between PF A, B and C. There is consensus among all reports that PF negatively affected the postoperative course in patients after PD.^{59,60} Our experience with PF was similar. In PD, the high mean amylase on drains or amylase more than 7 ukat/l predicted the onset of complications, especially if surgical complications were involved (OAC, ASC and PL). However, exception were AA where the mean amylases on drains were low proving that abscesses did not originate from pancreatic leak. PF A was not associated with any serious morbidity in postoperative course of our patients. Patients with OAC, ASC, AGC, BC, PL, PF C and high mean amylase or amylase more than 7 ukat/l are at a higher risk to die within 30 or 90 days. Although, most

studies agree about the impact of PF on morbidity and mortality, there is less consensus for how to prevent the occurrence of PF. Most effort is focused on how to perform a save anastomosis in case of soft friable pancreas texture with a thin pancreatic duct.^{5-7,10,61,62}

Both periods (P1 and P2) were comparable regarding almost all clinicopathological factors except for type of pancreatic resection and vascular reconstructions, and the count of performed TPs. There were more TPs in P2 as in P1 (20.8% vs. 4.2%). Both types of pancreatectomies were comparable regarding age, physical status, tumor markers, mean bilirubin value, morbidity and mortality. Logically, there were no PF in TP. In addition to other indications, TP was performed in 11 patients with pancreas remnant unsuitable for anastomosis. The indications for TP must be posed very responsible, even the inform consent must be done preoperatively in this issue.^{24,41,43} The morbidity was stable within the whole study period, but 30- and 90-day mortality became twofold lower in P2 (3.5% and 5.7%), although without a significant correlation.

Most subtypes of complications did not compromise the long-term survival in our cohort of patients. The exceptions were PLs in PDs and BCs in PDs and TPs where the 5-year survival was significantly compromised. On the other hand, in patients who survived any of these complications the long-term survival was not impacted by any type of complications.^{59,60,63,64}

In conclusion, the present study indicates that amylase rich secret on drains and higher mean age are independent indicator for OAC whereas. PL and BC proved as an independent predictor for 30-day mortality, and physical status, OAC and PF C for 90-day mortality. EBD, smaller size of tumor and NPC can provoke complications; however, there was no repercussion on postoperative mortality. Even though the decrease in 30- and 90-day mortality (3.5% and 5%) tightly missed the significance in our cohort of patients, the trends of better surgery in pancreatic resections in our institution seemed to be encouraging. Most subtypes of complications did not compromise the long-term survival in our cohort of patients. The exceptions were specific complications like PLs and BCs where the 5-year survival was significantly compromised. On the other hand, in patients who survived these complications, the long-term survival was not impaired by any type of complications. The worse scenario in pancreatic resection is an older patient in bad physical condition having low sized tumor

or NPC, amylase reach output on drains after resection, and eventually BC.

References

- Ho C-K, Kleeff J, Friess H, Büchler MW. Complications of pancreatic surgery. *HPB (Oxford)* 2005; **7**: 99-108. doi:10.1080/13651820510028936
- Kapoor VK. Complications of pancreato-duodenectomy. *Ceskoslovenske Chir Spolecnosti* 2016; **95**: 53-9.
- Penumadu P, Barreto SG, Goel M, Shrikhande SV. Pancreatoduodenectomy - preventing complications. *Indian J Surg Oncol* 2015; **6**: 6-15. doi:10.1007/s13193-013-0286-z
- Ren S, Liu P, Zhou N, Dong J, Liu R, Ji W. Complications after pancreaticoduodenectomy for pancreatic cancer: a retrospective study. *Int Surg* 2011; **96**: 220-7.
- Assumpcao L, Cameron JL, Wolfgang CL, Edil B, Choti MA, Herman JM, et al. Incidence and management of chyle leaks following pancreatic resection: a high volume single-center institutional experience. *J Gastrointest Surg* 2008; **12**: 1915-23. doi:10.1007/s11605-008-0619-3
- van Berge Henegouwen MI, De Wit LT, Van Gulik TM, Obertop H, Gouma DJ. Incidence, risk factors, and treatment of pancreatic leakage after pancreatoduodenectomy: drainage versus resection of the pancreatic remnant. *J Am Coll Surg* 1997; **185**: 18-24
- Vin Y, Sima CS, Getrajdman GI, Brown KT, Covey A, Brennan MF, et al. Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. *J Am Coll Surg* 2008; **207**: 490-8. doi:10.1016/j.jamcollsurg.2008.05.003
- Sperti C, Pasquali C, Ferronato A, Pedrazzoli S. Median pancreatectomy for tumors of the neck and body of the pancreas. *J Am Coll Surg* 2000; **190**: 711-6.
- Bourgouin S, Ewald J, Mancini J, Moutardier V, Delpero J-R, Le Treut Y-P. Predictive factors of severe complications for ampullary, bile duct and duodenal cancers following pancreaticoduodenectomy: Multivariate analysis of a 10-year multicentre retrospective series. *Surgeon* 2015; pii: S1479-666X(15)00118-3. doi:10.1016/j.surge.2015.11.003
- Machado NO. Pancreatic fistula after pancreatectomy: definitions, risk factors, preventive measures, and management-review. *Int J Surg Oncol* 2012; **2012**: 602478. doi:10.1155/2012/602478
- Hashimoto Y, Traverso LW. Pancreatic anastomotic failure rate after pancreatoduodenectomy decreases with microsurgery. *J Am Coll Surg* 2010; **211**: 510-21. doi:10.1016/j.jamcollsurg.2010.06.018
- Riall TS, Sheffield KM, Kuo Y-F, Townsend CM, Goodwin JS. Resection benefits older adults with locoregional pancreatic cancer despite greater short-term morbidity and mortality. *J Am Geriatr Soc* 2011; **59**: 647-54. doi:10.1111/j.1532-5415.2011.03353.x
- Riall TS. What is the effect of age on pancreatic resection? *Adv Surg* 2009; **43**: 233-49.
- Vollmer CM, Sanchez N, Gondek S, McAuliffe J, Kent TS, Christein JD, et al. A root-cause analysis of mortality following major pancreatectomy. *J Gastrointest Surg* 2012; **16**: 89-102. Discussion 102-3. doi:10.1007/s11605-011-1753-x
- Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, et al. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. *Ann Surg* 1997; **226**: 248-257. Discussion 257-60.
- Partelli S, Pecorelli N, Muffatti F, Belfiori G, Crippa S, Piazzai F, et al. Early postoperative prediction of clinically relevant pancreatic fistula after pancreatoduodenectomy: usefulness of C-reactive protein. *HPB (Oxford)* 2017; **19**: 580-6. doi:10.1016/j.hpb.2017.03.001
- Sperti C, Moletta L, Pozza G. Pancreatic resection in very elderly patients: A critical analysis of existing evidence. *World J Gastrointest Oncol* 2017; **9**: 30-6. doi:10.4251/wjgo.v9.i1.30
- Crea N, Di Fabio F, Pata G, Nascimbeni R. APACHE II, POSSUM, and ASA scores and the risk of perioperative complications in patients with colorectal disease. *Ann Ital Chir* 2009; **80**: 177-81.
- Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004; **240**: 205-13.
- Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. *Surgery* 2005; **138**: 8-13. doi:10.1016/j.surg.2005.05.001
- Rosenberg L. Treatment of pancreatic cancer. Promises and problems of tamoxifen, somatostatin analogs, and gemcitabine. *Int J Pancreatol* 1997; **22**: 81-93. doi:10.1007/BF02787465
- Neoptolemos JP, Russell RC, Bramhall S, Theis B. Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. UK Pancreatic Cancer Group. *Br J Surg* 1997; **84**: 1370-6.
- Dominguez-Comesaña E, Gonzalez-Rodriguez FJ, Ulla-Rocha JL, Ledesma-Fernandez A, Portela-Serra JL, Piñon-Cimadevila MÁ. Morbidity and mortality in pancreatic resection. *Cirugia Espanola* 2013; **91**: 651-8. doi:10.1016/j.ciresp.2012.12.004
- Stauffer JA, Nguyen JH, Heckman MG, Grewal MS, Dougherty M, Gill KRS, et al. Patient outcomes after total pancreatectomy: a single centre contemporary experience. *HPB* 2009; **11**: 483-92. doi:10.1111/j.1477-2574.2009.00077.x
- Riediger H, Adam U, Utzolino S, Neeff HP, Hopt UT, Makowicz F. Perioperative outcome after pancreatic head resection: a 10-year series of a specialized surgeon in a university hospital and a community hospital. *J Gastrointest Surg* 2014; **18**: 1434-40. doi:10.1007/s11605-014-2555-8
- Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. *J Am Coll Surg* 2015; **220**: 530-6. doi:10.1016/j.jamcollsurg.2014.12.031
- Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. *Ann Surg* 1993; **217**: 430-5.
- Romano G, Agrusa A, Galia M, Di Buono G, Chianetta D, Sorce V, et al. Whipple's pancreaticoduodenectomy: Surgical technique and perioperative clinical outcomes in a single center. *Int J Surg* 2015; **21(Suppl 1)**: S68-71. doi:10.1016/j.ijssu.2015.06.062
- Álamo JM, Marín LM, Suarez G, Bernal C, Serrano J, Barrera L, et al. Improving outcomes in pancreatic cancer: Key points in perioperative management. *World J Gastroenterol* 2014; **20**: 14237-45. doi:10.3748/wjg.v20.i39.14237
- Jenkins LJ, Parmar AD, Han Y, Duncan CB, Sheffield KM, Brown KM, et al. Current trends in preoperative biliary stenting in patients with pancreatic cancer. *Surgery* 2013; **154**: 179-89. doi:10.1016/j.surg.2013.03.016
- Singal AK, Ross WA, Guturu P, Varadhachary GR, Javle M, Jaganmohan SR, et al. Self-expanding metal stents for biliary drainage in patients with resectable pancreatic cancer: single-center experience with 79 cases. *Dig Dis Sci* 2011; **56**: 3678-84. doi:10.1007/s10620-011-1815-7
- Sahora K, Morales-Oyarvide V, Ferrone C, Fong ZV, Warshaw AL, Lillemoe KD, et al. Preoperative biliary drainage does not increase major complications in pancreaticoduodenectomy: a large single center experience from the Massachusetts General Hospital. *J Hepato-Biliary-Pancreat Sci* 2016; **23**: 181-7. doi:10.1002/jhbp.322
- Pisters PW, Hudec WA, Hess KR, Lee JE, Vauthey JN, Lahoti S, et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. *Ann Surg* 2001; **234**: 47-55.
- Scheufele F, Schorn S, Demir IE, Sargut M, Tiefertunk E, Calavrezos L, et al. Preoperative biliary stenting versus operation first in jaundiced patients due to malignant lesions in the pancreatic head: A meta-analysis of current literature. *Surgery* 2017; **161**: 939-50. doi:10.1016/j.surg.2016.11.001
- Cavell LK, Allen PJ, Vinoya C, Eaton AA, Gonen M, Gerdes H, et al. Biliary self-expandable metal stents do not adversely affect pancreaticoduodenectomy. *Am J Gastroenterol* 2013; **108**: 1168-73. doi:10.1038/ajg.2013.93
- Tsuboi T, Sasaki T, Serikawa M, Ishii Y, Mouri T, Shimizu A, et al. Preoperative biliary drainage in cases of borderline resectable pancreatic cancer treated with neoadjuvant chemotherapy and surgery. *Gastroenterol Res Pract* 2016; **2016**: 7968201.

37. Xiong J-J, Nunes QM, Huang W, Pathak S, Wei A-L, Tan C-L, et al. Preoperative biliary drainage in patients with hilar cholangiocarcinoma undergoing major hepatectomy. *World J Gastroenterol* 2013; **19**: 8731-9. doi:10.3748/wjg.v19.i46.8731
38. Kishi Y, Shimada K, Nara S, Esaki M, Kosuge T. The type of preoperative biliary drainage predicts short-term outcome after major hepatectomy. *Langenbecks Arch Surg* 2016; **401**: 503-11. doi:10.1007/s00423-016-1427-y
39. Coates JM, Beal SH, Russo JE, Vanderveen KA, Chen SL, Bold RJ, et al. Negligible effect of selective preoperative biliary drainage on perioperative resuscitation, morbidity, and mortality in patients undergoing pancreaticoduodenectomy. *Arch Surg Chic Ill 1960* 2009; **144**: 841-7. doi:10.1001/archsurg.2009.152
40. Ferrero A, Lo Tesoriere R, Viganò L, Caggiano L, Sgotto E, Capussotti L. Preoperative biliary drainage increases infectious complications after hepatectomy for proximal bile duct tumor obstruction. *World J Surg* 2009; **33**: 318-25. doi:10.1007/s00268-008-9830-3
41. Del Chiaro M, Rangelova E, Segersvärd R, Arnelo U. Are there still indications for total pancreatectomy? *Updat Surg* 2016; **68**: 257-63. doi:10.1007/s13304-016-0388-6
42. Müller MW, Friess H, Kleeff J, Dahmen R, Wagner M, Hinz U, et al. Is there still a role for total pancreatectomy? *Ann Surg* 2007; **246**: 966-75. doi:10.1097/SLA.0b013e31815c2ca3
43. Billings BJ, Christein JD, Harmsen WS, Harrington JR, Chari ST, Que FG, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? *J Gastrointest Surg* 2005; **9**: 1059-66. doi:10.1016/j.gasur.2005.05.014
44. White MA, Agle SC, Fuhr HM, Mehaffey JH, Waibel BH, Zervos EE. Impact of pancreatic cancer and subsequent resection on glycemic control in diabetic and nondiabetic patients. *Am Surg* 2011; **77**: 1032-7.
45. Chu CK, Mazo AE, Sarmiento JM, Staley CA, Adsay NV, Umpierrez GE, et al. Impact of diabetes mellitus on perioperative outcomes after resection for pancreatic adenocarcinoma. *J Am Coll Surg* 2010; **210**: 463-73. doi:10.1016/j.jamcollsurg.2009.12.029
46. Malleo G, Mazzarella F, Malpaga A, Marchegiani G, Salvia R, Bassi C, et al. Diabetes mellitus does not impact on clinically relevant pancreatic fistula after partial pancreatic resection for ductal adenocarcinoma. *Surgery* 2013; **153**: 641-50. doi:10.1016/j.surg.2012.10.015
47. Marsoner K, Langeder R, Csengeri D, Sodeck G, Mischinger HJ, Kornprat P. Portal vein resection in advanced pancreatic adenocarcinoma: is it worth the risk? *Wien Klin Wochenschr* 2016; **128**: 566-72. doi:10.1007/s00508-016-1024-7
48. Hoshimoto S, Hishinuma S, Shirakawa H, Tomikawa M, Ozawa I, Wakamatsu S, et al. Reassessment of the clinical significance of portal-superior mesenteric vein invasion in borderline resectable pancreatic cancer. *Eur J Surg Oncol* 2017; **43**: 1068-75. doi:10.1016/j.jamcollsurg.2010.06.018
49. Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT. Postoperative morbidity and long-term survival after pancreaticoduodenectomy with superior mesenteric-portal vein resection. *J Gastrointest Surg* 2006; **10**: 1106-15. doi:10.1016/j.gassur.2006.04.002
50. Kulemann B, Hoepfner J, Wittel U, Glatz T, Keck T, Wellner UF, et al. Perioperative and long-term outcome after standard pancreaticoduodenectomy, additional portal vein and multivisceral resection for pancreatic head cancer. *J Gastrointest Surg* 2015; **19**: 438-44. doi:10.1007/s11605-014-2725-8
51. Cheung TT, Poon RTP, Chok KSH, Chan ACY, Tsang SHY, Dai WC, et al. Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability. *World J Gastroenterol* 2014; **20**: 17448-55. doi:10.3748/wjg.v20.i46.17448
52. Flis V, Potrc S, Kobilica N, Ivanec A. Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resection. *Radiol Oncol* 2016; **50**: 321-8. doi:10.1515/raon-2015-0017
53. Park JR, Li F, Oza VM, Sklaw BC, Cronley KM, Wellner M, et al. High-grade pancreatic intraepithelial lesions: prevalence and implications in pancreatic neoplasia. *Hepatobiliary Pancreat Dis Int* 2017; **16**: 202-8.
54. Hwang IK, Kim H, Lee YS, Kim J, Cho JY, Yoon Y-S, et al. Presence of pancreatic intraepithelial neoplasia-3 in a background of chronic pancreatitis in pancreatic cancer patients. *Cancer Sci* 2015; **106**: 1408-13. doi:10.1111/cas.12744
55. Thorat A, Huang W-H, Yeh T-S, Jan Y-Y, Hwang T-L. Pancreatic ductal adenocarcinoma presenting with acute and chronic pancreatitis as initial presentation: is prognosis better? A comparison study. *Hepatogastroenterology* 2014; **61**: 2110-6.
56. Ahmad Z, Din NU, Minhas K, Moeen S, Ahmed A. Epidemiologic data, tumor size, histologic tumor type and grade, pathologic staging and follow up in cancers of the ampullary region and head of pancreas in 311 Whipple resection specimens of pakistani patients. *Asian Pac J Cancer Prev* 2015; **16**: 7541-6.
57. Perysinakis I, Avlonitis S, Georgiadou D, Tspiras H, Margaritis I. Five-year actual survival after pancreaticoduodenectomy for pancreatic head cancer. *ANZ J Surg* 2015; **85**: 183-6. doi:10.1111/ans.12422
58. Petermann D, Demartines N, Schäfer M. Is tumour size an underestimated feature in the current TNM system for malignancies of the pancreatic head? *HPB* 2013; **15**: 872-81. doi:10.1111/hpb.12052
59. Cullen JJ, Sarr MG, Ilstrup DM. Pancreatic anastomotic leak after pancreaticoduodenectomy: incidence, significance, and management. *Am J Surg* 1994; **168**: 295-8.
60. Seetharam P, Rodrigues GS. Postoperative pancreatic fistula: A surgeon's nightmare! An insight with a detailed literature review. *JOP J Pancreas* 2015; **16**: 115-24.
61. Suzuki Y, Fujino Y, Tanioka Y, Ajiki T, Hiraoka K, Takada M, et al. Factors influencing hepaticojejunostomy leak following pancreaticoduodenal resection; importance of anastomotic leak test. *Hepatogastroenterology* 2003; **50**: 254-7.
62. Conzo G, Gambardella C, Tartaglia E, Sciascia V, Mauriello C, Napolitano S, et al. Pancreatic fistula following pancreaticoduodenectomy. Evaluation of different surgical approaches in the management of pancreatic stump. Literature review. *Int J Surg* 2015; **21(Suppl 1)**: S4-9. doi:10.1016/j.ijsu.2015.04.088
63. Balachandran P, Sikora SS, Raghavendra Rao RV, Kumar A, Saxena R, Kapoor VK. Haemorrhagic complications of pancreaticoduodenectomy. *ANZ J Surg* 2004; **74**: 945-50. doi:10.1111/j.1445-1433.2004.03212.x
64. Rumstadt B, Schwab M, Korth P, Samman M, Trede M. Hemorrhage after pancreaticoduodenectomy. *Ann Surg* 1998; **227**: 236-41.